Exchange & Returns Information
Review Details
(0)
| Generic For | TAFINLAR |
|---|---|
| Active Ingredient | DABRAFENIB |
| Strength | 50MG |
| Manufacturer | NOVARTIS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 28 CAPSULES | $ 32.50 | $ 910.00 |
$ 773.50
Apply ZARVY26 (-15%)
You save $ 136.50
|
||
| 2 BOXES - 56 CAPSULES | $ 30.80 |
5% $ 1,820.00
$ 1,725.00
|
$ 1,466.25
Apply ZARVY26 (-15%)
You save $ 258.75
|
||
| ★ Best Value 3 BOXES - 84 CAPSULES | $ 29.29 |
10% $ 2,730.00
$ 2,460.00
|
$ 2,091.00
Apply ZARVY26 (-15%)
You save $ 369.00
|
Reference information will be available soon.
Rafinlar 50mg is an oral anticancer medication containing dabrafenib, a potent BRAF inhibitor specifically designed to target tumors with BRAF V600E or V600K mutations. It is utilized in advanced cancers including metastatic melanoma, non-small cell lung cancer (NSCLC), anaplastic thyroid cancer (ATC), and select pediatric solid tumors. Dabrafenib inhibits abnormal BRAF kinase activity in the MAPK pathway, preventing proliferation in mutation-positive tumors. It is often administered in combination with trametinib, a MEK inhibitor, for enhanced efficacy and delayed resistance development. Trusted online pharmacy sources provide safe access to Rafinlar for adult and pediatric patients.
Dabrafenib selectively inhibits mutant BRAF V600 kinases within the MAPK/ERK pathway, disrupting oncogenic signaling.
Induces apoptosis and reduces tumor burden in mutation-positive cancers.
Combination with trametinib enhances pathway blockade, delays resistance, and improves overall response rates.
Cell proliferation suppression is effective across melanoma, NSCLC, anaplastic thyroid cancer, and pediatric solid tumors.
Integration into broader treatment plans can complement supportive therapies where relevant, occasionally overlapping with dermatologic adjuncts such as Tretinoin Cream, Isotretinoin, or Acne Treatment for skin-related adverse events.
Melanoma (Unresectable or Metastatic, Adults): 150 mg orally twice daily, continue until progression or unacceptable toxicity; adjuvant post-surgery up to 12 months if tolerated. BRAF V600E required for monotherapy, V600E/V600K for combination therapy.
NSCLC (Adults): 150 mg orally twice daily with trametinib, BRAF V600E required.
Anaplastic Thyroid Cancer (ATC, Adults): 150 mg orally twice daily with trametinib, BRAF V600E required.
Solid Tumors (Adults): 150 mg orally twice daily, continue until progression or toxicity; use under accelerated approval. Not for wild-type BRAF tumors.
Pediatric Dosing (≥1 year): Capsules—26–37 kg: 75 mg twice daily; 38–50 kg: 100 mg twice daily; ≥51 kg: 150 mg twice daily. Oral suspension dosing weight-based 8 kg to ≥51 kg. Confirm BRAF V600E mutation prior to initiation.
Administer at least 1 hour before or 2 hours after meals. Do not open or crush capsules. Monitor liver function, skin, blood glucose, and vision regularly.
Store at 20–25°C (68–77°F) in the original container. Protect from moisture, heat, and light. Do not refrigerate or freeze. Keep out of reach of children.
Common: fever, fatigue, joint pain, hyperkeratosis, and skin rash.
Serious: cutaneous squamous cell carcinoma, hyperglycemia, uveitis, hemorrhage, cardiac dysfunction.
Pediatric patients require monitoring for growth and development.
Regular skin checks, ophthalmologic exams, and blood work are recommended throughout treatment.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
